| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorobenzenes | 28 | 2015 | 179 | 4.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 67 | 2024 | 3245 | 3.530 |
Why?
|
| Pharmacoepidemiology | 24 | 2024 | 350 | 3.260 |
Why?
|
| Propensity Score | 37 | 2023 | 1913 | 2.890 |
Why?
|
| Comparative Effectiveness Research | 14 | 2019 | 709 | 2.540 |
Why?
|
| Sulfonamides | 29 | 2015 | 1978 | 2.530 |
Why?
|
| Cardiovascular Diseases | 117 | 2024 | 15500 | 2.530 |
Why?
|
| Models, Statistical | 32 | 2021 | 5079 | 2.240 |
Why?
|
| C-Reactive Protein | 54 | 2023 | 3826 | 2.180 |
Why?
|
| Pyrimidines | 29 | 2017 | 3028 | 2.170 |
Why?
|
| Epidemiologic Methods | 18 | 2017 | 1336 | 2.090 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 12 | 2024 | 311 | 1.720 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 38 | 2020 | 2273 | 1.700 |
Why?
|
| Research Design | 23 | 2024 | 6180 | 1.460 |
Why?
|
| Myocardial Infarction | 61 | 2024 | 11460 | 1.460 |
Why?
|
| Methotrexate | 14 | 2024 | 1719 | 1.440 |
Why?
|
| Psoriasis | 5 | 2024 | 950 | 1.420 |
Why?
|
| Venous Thromboembolism | 15 | 2022 | 1866 | 1.400 |
Why?
|
| Cholesterol, LDL | 34 | 2024 | 2382 | 1.380 |
Why?
|
| Interleukin-1beta | 13 | 2022 | 999 | 1.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2024 | 12148 | 1.340 |
Why?
|
| Cataract | 28 | 2024 | 832 | 1.340 |
Why?
|
| Data Interpretation, Statistical | 29 | 2020 | 2691 | 1.340 |
Why?
|
| Aged | 420 | 2024 | 169289 | 1.300 |
Why?
|
| Primary Prevention | 19 | 2024 | 1186 | 1.250 |
Why?
|
| Venous Thrombosis | 12 | 2020 | 1303 | 1.230 |
Why?
|
| Hypertension | 55 | 2023 | 8540 | 1.220 |
Why?
|
| Blood Pressure | 38 | 2019 | 8481 | 1.200 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 13 | 2020 | 321 | 1.190 |
Why?
|
| Vitamin E | 19 | 2022 | 872 | 1.180 |
Why?
|
| Double-Blind Method | 94 | 2024 | 12341 | 1.180 |
Why?
|
| Mortality | 27 | 2024 | 2901 | 1.150 |
Why?
|
| Randomized Controlled Trials as Topic | 50 | 2023 | 10209 | 1.150 |
Why?
|
| Insurance Claim Review | 13 | 2021 | 741 | 1.050 |
Why?
|
| Warfarin | 18 | 2024 | 1483 | 1.040 |
Why?
|
| Humans | 656 | 2024 | 761504 | 1.040 |
Why?
|
| Incidence | 95 | 2024 | 21353 | 0.990 |
Why?
|
| Medicare | 54 | 2024 | 6770 | 0.990 |
Why?
|
| Hypoglycemic Agents | 23 | 2024 | 3085 | 0.980 |
Why?
|
| Frail Elderly | 12 | 2024 | 765 | 0.970 |
Why?
|
| Atherosclerosis | 16 | 2024 | 3408 | 0.960 |
Why?
|
| Cohort Studies | 112 | 2024 | 41487 | 0.940 |
Why?
|
| Middle Aged | 349 | 2024 | 220895 | 0.940 |
Why?
|
| Risk Factors | 203 | 2024 | 74206 | 0.930 |
Why?
|
| Insurance, Pharmaceutical Services | 11 | 2013 | 348 | 0.910 |
Why?
|
| Female | 415 | 2024 | 392644 | 0.900 |
Why?
|
| Regression Analysis | 36 | 2023 | 6343 | 0.900 |
Why?
|
| Coronary Disease | 26 | 2024 | 5914 | 0.890 |
Why?
|
| Patient Compliance | 22 | 2012 | 2690 | 0.890 |
Why?
|
| Computer Simulation | 21 | 2023 | 6240 | 0.890 |
Why?
|
| Male | 434 | 2024 | 360804 | 0.870 |
Why?
|
| Aspirin | 34 | 2011 | 3133 | 0.860 |
Why?
|
| Anticoagulants | 21 | 2024 | 4812 | 0.820 |
Why?
|
| Vitamins | 15 | 2022 | 1635 | 0.810 |
Why?
|
| Macular Degeneration | 18 | 2020 | 1007 | 0.810 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2024 | 178 | 0.810 |
Why?
|
| Statistics, Nonparametric | 9 | 2018 | 2850 | 0.810 |
Why?
|
| United States | 157 | 2024 | 72334 | 0.800 |
Why?
|
| Cost Sharing | 7 | 2008 | 409 | 0.770 |
Why?
|
| Aged, 80 and over | 185 | 2024 | 58976 | 0.770 |
Why?
|
| Vitiligo | 1 | 2022 | 97 | 0.760 |
Why?
|
| Arthritis, Rheumatoid | 15 | 2024 | 3763 | 0.750 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 675 | 0.740 |
Why?
|
| Dermatitis, Atopic | 3 | 2024 | 731 | 0.740 |
Why?
|
| Antihypertensive Agents | 27 | 2023 | 2024 | 0.730 |
Why?
|
| Pulmonary Embolism | 10 | 2022 | 2567 | 0.720 |
Why?
|
| New Jersey | 27 | 2011 | 295 | 0.720 |
Why?
|
| Likelihood Functions | 11 | 2023 | 992 | 0.710 |
Why?
|
| Stroke | 33 | 2024 | 9757 | 0.710 |
Why?
|
| Proportional Hazards Models | 69 | 2023 | 12463 | 0.710 |
Why?
|
| Epidemiologic Research Design | 8 | 2014 | 368 | 0.680 |
Why?
|
| Alopecia Areata | 1 | 2022 | 128 | 0.680 |
Why?
|
| Antirheumatic Agents | 10 | 2024 | 1372 | 0.650 |
Why?
|
| Hypercholesterolemia | 7 | 2018 | 1141 | 0.650 |
Why?
|
| Biometry | 5 | 2010 | 563 | 0.650 |
Why?
|
| Cholesterol, HDL | 21 | 2022 | 1814 | 0.640 |
Why?
|
| Cause of Death | 23 | 2024 | 3683 | 0.640 |
Why?
|
| Heart Failure | 29 | 2024 | 11669 | 0.640 |
Why?
|
| Hyperlipidemias | 9 | 2023 | 771 | 0.610 |
Why?
|
| Benzhydryl Compounds | 5 | 2024 | 916 | 0.600 |
Why?
|
| Antioxidants | 18 | 2020 | 1668 | 0.590 |
Why?
|
| Acetaminophen | 4 | 2020 | 554 | 0.590 |
Why?
|
| Biostatistics | 4 | 2024 | 164 | 0.580 |
Why?
|
| Metformin | 6 | 2023 | 906 | 0.570 |
Why?
|
| Glucosides | 5 | 2024 | 512 | 0.570 |
Why?
|
| Follow-Up Studies | 105 | 2024 | 39106 | 0.570 |
Why?
|
| Thromboembolism | 7 | 2018 | 995 | 0.570 |
Why?
|
| Gout | 7 | 2023 | 621 | 0.570 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 5127 | 0.570 |
Why?
|
| Comorbidity | 26 | 2018 | 10508 | 0.530 |
Why?
|
| Eye Diseases | 7 | 2024 | 653 | 0.520 |
Why?
|
| Risk Assessment | 50 | 2024 | 23995 | 0.510 |
Why?
|
| Geriatric Assessment | 8 | 2020 | 1410 | 0.510 |
Why?
|
| Cholesterol | 17 | 2023 | 2904 | 0.510 |
Why?
|
| Arthritis, Psoriatic | 1 | 2018 | 219 | 0.510 |
Why?
|
| Ascorbic Acid | 9 | 2022 | 655 | 0.500 |
Why?
|
| Sample Size | 7 | 2024 | 841 | 0.490 |
Why?
|
| beta Carotene | 15 | 2009 | 523 | 0.490 |
Why?
|
| Causality | 8 | 2023 | 1242 | 0.490 |
Why?
|
| Logistic Models | 46 | 2021 | 13255 | 0.480 |
Why?
|
| British Columbia | 16 | 2012 | 241 | 0.480 |
Why?
|
| Interleukin-6 | 6 | 2022 | 3208 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 9177 | 0.480 |
Why?
|
| Prospective Studies | 99 | 2024 | 54425 | 0.480 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2010 | 1007 | 0.470 |
Why?
|
| Drug Costs | 8 | 2012 | 1183 | 0.460 |
Why?
|
| Algorithms | 19 | 2024 | 14031 | 0.460 |
Why?
|
| Lipoproteins, LDL | 5 | 2020 | 642 | 0.460 |
Why?
|
| Systole | 10 | 2011 | 936 | 0.460 |
Why?
|
| Adult | 193 | 2024 | 221177 | 0.450 |
Why?
|
| Hypolipidemic Agents | 7 | 2022 | 609 | 0.450 |
Why?
|
| Visual Acuity | 28 | 2020 | 2672 | 0.450 |
Why?
|
| Women's Health | 13 | 2018 | 2065 | 0.450 |
Why?
|
| Physicians | 36 | 2022 | 4591 | 0.450 |
Why?
|
| Dietary Supplements | 15 | 2024 | 3415 | 0.440 |
Why?
|
| Government Regulation | 1 | 2018 | 524 | 0.440 |
Why?
|
| Multivariate Analysis | 33 | 2018 | 12059 | 0.440 |
Why?
|
| Cluster Analysis | 6 | 2010 | 2707 | 0.430 |
Why?
|
| Anticholesteremic Agents | 9 | 2017 | 966 | 0.430 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2012 | 276 | 0.430 |
Why?
|
| Osteoarthritis | 6 | 2024 | 1063 | 0.430 |
Why?
|
| Medicare Part D | 6 | 2013 | 355 | 0.430 |
Why?
|
| Hemorrhage | 11 | 2024 | 3424 | 0.430 |
Why?
|
| Risk | 51 | 2016 | 9610 | 0.430 |
Why?
|
| Colitis, Ulcerative | 2 | 2022 | 1922 | 0.420 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2024 | 2751 | 0.420 |
Why?
|
| Treatment Outcome | 67 | 2024 | 64680 | 0.420 |
Why?
|
| Electronic Health Records | 10 | 2024 | 4811 | 0.410 |
Why?
|
| Prescription Drugs | 7 | 2024 | 631 | 0.410 |
Why?
|
| Software | 4 | 2023 | 4434 | 0.410 |
Why?
|
| Inflammation | 18 | 2023 | 10773 | 0.410 |
Why?
|
| Time Factors | 63 | 2024 | 39967 | 0.410 |
Why?
|
| Lipids | 15 | 2024 | 3341 | 0.410 |
Why?
|
| Diabetic Retinopathy | 10 | 2023 | 1274 | 0.400 |
Why?
|
| Drug Prescriptions | 14 | 2018 | 1670 | 0.400 |
Why?
|
| Anti-Inflammatory Agents | 7 | 2020 | 1809 | 0.400 |
Why?
|
| Coronary Artery Disease | 8 | 2018 | 6403 | 0.400 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 2243 | 0.400 |
Why?
|
| Data Collection | 7 | 2019 | 3322 | 0.400 |
Why?
|
| Drug Utilization | 15 | 2012 | 1188 | 0.390 |
Why?
|
| Glaucoma | 9 | 2023 | 1185 | 0.390 |
Why?
|
| Matched-Pair Analysis | 5 | 2021 | 284 | 0.390 |
Why?
|
| Aging | 29 | 2015 | 8708 | 0.380 |
Why?
|
| Health Policy | 5 | 2018 | 2684 | 0.380 |
Why?
|
| Pennsylvania | 15 | 2013 | 613 | 0.380 |
Why?
|
| Alcohol Drinking | 26 | 2017 | 4028 | 0.380 |
Why?
|
| Cataract Extraction | 10 | 2016 | 467 | 0.380 |
Why?
|
| Age Factors | 42 | 2021 | 18395 | 0.380 |
Why?
|
| Databases, Factual | 16 | 2020 | 7967 | 0.380 |
Why?
|
| Lipoprotein(a) | 3 | 2024 | 480 | 0.380 |
Why?
|
| Cardiovascular Agents | 7 | 2018 | 840 | 0.380 |
Why?
|
| Smoking | 32 | 2021 | 9053 | 0.360 |
Why?
|
| Cyclooxygenase Inhibitors | 7 | 2017 | 361 | 0.360 |
Why?
|
| Medication Adherence | 8 | 2023 | 2176 | 0.350 |
Why?
|
| Prescription Fees | 4 | 2012 | 153 | 0.350 |
Why?
|
| Diastole | 7 | 2011 | 782 | 0.350 |
Why?
|
| Sulfonylurea Compounds | 4 | 2020 | 219 | 0.350 |
Why?
|
| Evidence-Based Medicine | 9 | 2021 | 3688 | 0.350 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2020 | 370 | 0.350 |
Why?
|
| Cognition | 7 | 2020 | 6990 | 0.350 |
Why?
|
| Fibrinolytic Agents | 3 | 2009 | 2084 | 0.350 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 2422 | 0.340 |
Why?
|
| Genetic Markers | 3 | 2020 | 2601 | 0.340 |
Why?
|
| Risk Adjustment | 5 | 2011 | 600 | 0.340 |
Why?
|
| Crohn Disease | 1 | 2022 | 2279 | 0.340 |
Why?
|
| Intercellular Adhesion Molecule-1 | 6 | 2016 | 1126 | 0.340 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2023 | 1241 | 0.330 |
Why?
|
| Odds Ratio | 34 | 2020 | 9646 | 0.330 |
Why?
|
| Hypertriglyceridemia | 2 | 2022 | 293 | 0.330 |
Why?
|
| European Union | 1 | 2010 | 157 | 0.330 |
Why?
|
| Analgesics, Opioid | 11 | 2024 | 3808 | 0.330 |
Why?
|
| Monte Carlo Method | 7 | 2015 | 1258 | 0.320 |
Why?
|
| Antipsychotic Agents | 11 | 2018 | 3067 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 13 | 2021 | 1516 | 0.320 |
Why?
|
| Colorectal Neoplasms | 9 | 2017 | 6935 | 0.320 |
Why?
|
| Linear Models | 15 | 2018 | 5871 | 0.320 |
Why?
|
| Hydroxychloroquine | 5 | 2024 | 426 | 0.320 |
Why?
|
| Case-Control Studies | 39 | 2024 | 22176 | 0.320 |
Why?
|
| Dyslipidemias | 5 | 2024 | 868 | 0.300 |
Why?
|
| Uveal Neoplasms | 12 | 1992 | 341 | 0.300 |
Why?
|
| Rhabdomyolysis | 4 | 2019 | 152 | 0.300 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2007 | 422 | 0.300 |
Why?
|
| Imidazolidines | 3 | 2004 | 38 | 0.300 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2019 | 1116 | 0.290 |
Why?
|
| Ophthalmology | 3 | 2024 | 550 | 0.290 |
Why?
|
| Patient Admission | 6 | 2019 | 1367 | 0.290 |
Why?
|
| Benzodiazepines | 7 | 2022 | 1132 | 0.290 |
Why?
|
| Secondary Prevention | 10 | 2018 | 1475 | 0.290 |
Why?
|
| Renal Dialysis | 6 | 2008 | 1797 | 0.290 |
Why?
|
| Visual Fields | 7 | 2017 | 1062 | 0.290 |
Why?
|
| Drug Administration Schedule | 12 | 2018 | 4853 | 0.280 |
Why?
|
| Health Services Research | 6 | 2008 | 1812 | 0.280 |
Why?
|
| Longitudinal Studies | 30 | 2021 | 14605 | 0.280 |
Why?
|
| Angina, Unstable | 6 | 2016 | 888 | 0.280 |
Why?
|
| Computer Security | 2 | 2019 | 261 | 0.280 |
Why?
|
| Personnel, Hospital | 2 | 2019 | 285 | 0.280 |
Why?
|
| Hydrochlorothiazide | 5 | 2009 | 94 | 0.280 |
Why?
|
| Eicosapentaenoic Acid | 4 | 2022 | 561 | 0.270 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 676 | 0.270 |
Why?
|
| Health Surveys | 9 | 2019 | 4061 | 0.270 |
Why?
|
| Sex Factors | 20 | 2020 | 10552 | 0.270 |
Why?
|
| Deductibles and Coinsurance | 5 | 2011 | 316 | 0.270 |
Why?
|
| Vascular Diseases | 5 | 2019 | 1161 | 0.270 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2019 | 452 | 0.270 |
Why?
|
| Triglycerides | 10 | 2022 | 2461 | 0.270 |
Why?
|
| Patient Selection | 8 | 2017 | 4244 | 0.260 |
Why?
|
| Drug Therapy, Combination | 12 | 2024 | 6310 | 0.260 |
Why?
|
| Thrombosis | 4 | 2020 | 2942 | 0.260 |
Why?
|
| Drug Utilization Review | 7 | 2007 | 248 | 0.260 |
Why?
|
| Biomedical Research | 3 | 2018 | 3429 | 0.260 |
Why?
|
| Fractures, Bone | 5 | 2024 | 2046 | 0.250 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 21012 | 0.250 |
Why?
|
| Tramadol | 2 | 2024 | 60 | 0.250 |
Why?
|
| Recurrence | 12 | 2018 | 8465 | 0.250 |
Why?
|
| Body Mass Index | 20 | 2024 | 12953 | 0.240 |
Why?
|
| Drug Monitoring | 4 | 2017 | 962 | 0.240 |
Why?
|
| Chronic Disease | 10 | 2022 | 9318 | 0.240 |
Why?
|
| Activities of Daily Living | 7 | 2020 | 2421 | 0.240 |
Why?
|
| Hospitalization | 28 | 2024 | 10723 | 0.240 |
Why?
|
| International Normalized Ratio | 6 | 2017 | 382 | 0.240 |
Why?
|
| Cross-Over Studies | 6 | 2019 | 2078 | 0.240 |
Why?
|
| Injections, Subcutaneous | 4 | 2019 | 681 | 0.240 |
Why?
|
| Acetylglucosamine | 2 | 2016 | 189 | 0.240 |
Why?
|
| Calcium Channel Blockers | 3 | 2003 | 694 | 0.240 |
Why?
|
| Uric Acid | 6 | 2023 | 807 | 0.240 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 244 | 0.240 |
Why?
|
| National Health Programs | 2 | 2009 | 440 | 0.240 |
Why?
|
| Predictive Value of Tests | 30 | 2020 | 15266 | 0.240 |
Why?
|
| Mixed Function Oxygenases | 3 | 2011 | 265 | 0.230 |
Why?
|
| Nephrology | 3 | 2002 | 263 | 0.230 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2005 | 308 | 0.230 |
Why?
|
| Antithrombins | 3 | 2019 | 294 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2019 | 10766 | 0.230 |
Why?
|
| Baclofen | 2 | 2022 | 120 | 0.230 |
Why?
|
| Cholecalciferol | 2 | 2019 | 553 | 0.230 |
Why?
|
| Drug Interactions | 6 | 2021 | 1416 | 0.230 |
Why?
|
| Drug Approval | 2 | 2011 | 814 | 0.230 |
Why?
|
| Confidence Intervals | 15 | 2018 | 2927 | 0.230 |
Why?
|
| Gingival Diseases | 1 | 2004 | 36 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 8 | 2018 | 7390 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2018 | 3415 | 0.220 |
Why?
|
| Dihydropyridines | 1 | 2003 | 67 | 0.220 |
Why?
|
| Periodontal Index | 1 | 2004 | 151 | 0.220 |
Why?
|
| Insurance Coverage | 6 | 2013 | 1940 | 0.220 |
Why?
|
| Cross-Sectional Studies | 27 | 2020 | 26125 | 0.220 |
Why?
|
| Depression | 8 | 2018 | 8124 | 0.220 |
Why?
|
| Anticonvulsants | 4 | 2015 | 1906 | 0.220 |
Why?
|
| Public Health Informatics | 1 | 2004 | 109 | 0.220 |
Why?
|
| Fibrinogen | 4 | 2016 | 888 | 0.220 |
Why?
|
| Cholinergic Antagonists | 4 | 2009 | 168 | 0.220 |
Why?
|
| Vitamin B 12 | 3 | 2016 | 524 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 8 | 2003 | 2471 | 0.210 |
Why?
|
| Diet | 6 | 2017 | 8075 | 0.210 |
Why?
|
| Retrospective Studies | 60 | 2023 | 80636 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2024 | 3205 | 0.210 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.210 |
Why?
|
| Methocarbamol | 1 | 2022 | 8 | 0.210 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 352 | 0.210 |
Why?
|
| Awareness | 1 | 2007 | 648 | 0.210 |
Why?
|
| Markov Chains | 4 | 2005 | 966 | 0.210 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 407 | 0.210 |
Why?
|
| Diabetes Complications | 5 | 2018 | 1315 | 0.210 |
Why?
|
| Selection Bias | 4 | 2009 | 359 | 0.210 |
Why?
|
| Diabetes Mellitus | 10 | 2018 | 5840 | 0.200 |
Why?
|
| Polysaccharides | 3 | 2024 | 1014 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2024 | 1390 | 0.200 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2009 | 345 | 0.200 |
Why?
|
| Health Services for the Aged | 2 | 2006 | 259 | 0.200 |
Why?
|
| Retinitis Pigmentosa | 3 | 2017 | 397 | 0.200 |
Why?
|
| Hepatitis | 1 | 2024 | 228 | 0.200 |
Why?
|
| Survival Analysis | 12 | 2023 | 10090 | 0.200 |
Why?
|
| Pyrazoles | 5 | 2024 | 2009 | 0.200 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 277 | 0.190 |
Why?
|
| Kidney Diseases | 3 | 2008 | 2091 | 0.190 |
Why?
|
| Nutritional Status | 5 | 2018 | 1615 | 0.190 |
Why?
|
| Folic Acid | 4 | 2021 | 1323 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 3 | 2019 | 908 | 0.190 |
Why?
|
| Random Allocation | 4 | 2023 | 2395 | 0.190 |
Why?
|
| Polyglutamic Acid | 1 | 2021 | 47 | 0.190 |
Why?
|
| Self Care | 1 | 2007 | 796 | 0.190 |
Why?
|
| Valine | 3 | 2008 | 408 | 0.190 |
Why?
|
| Tetanus | 1 | 2021 | 51 | 0.190 |
Why?
|
| Diphtheria | 1 | 2021 | 33 | 0.190 |
Why?
|
| Socioeconomic Factors | 12 | 2024 | 7827 | 0.190 |
Why?
|
| PPAR alpha | 1 | 2022 | 175 | 0.190 |
Why?
|
| Neoplasms | 24 | 2019 | 22170 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 3 | 2008 | 1200 | 0.190 |
Why?
|
| Apolipoproteins B | 3 | 2021 | 386 | 0.190 |
Why?
|
| ROC Curve | 6 | 2021 | 3579 | 0.190 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2023 | 2118 | 0.180 |
Why?
|
| Phospholipids | 3 | 2014 | 786 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2017 | 730 | 0.180 |
Why?
|
| Health Status Indicators | 4 | 2019 | 970 | 0.180 |
Why?
|
| Whooping Cough | 1 | 2021 | 86 | 0.180 |
Why?
|
| Health Services Accessibility | 5 | 2020 | 5440 | 0.180 |
Why?
|
| Life Expectancy | 3 | 2024 | 1242 | 0.180 |
Why?
|
| Arteritis | 1 | 2022 | 158 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 147 | 0.180 |
Why?
|
| Vitamin B Complex | 2 | 2016 | 299 | 0.180 |
Why?
|
| Electronic Mail | 2 | 2019 | 213 | 0.180 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 1129 | 0.180 |
Why?
|
| Lorazepam | 1 | 2021 | 154 | 0.180 |
Why?
|
| Myocardial Revascularization | 5 | 2016 | 790 | 0.180 |
Why?
|
| Geriatrics | 1 | 2005 | 388 | 0.180 |
Why?
|
| Models, Theoretical | 4 | 2008 | 3575 | 0.180 |
Why?
|
| Nurses | 7 | 2017 | 2478 | 0.180 |
Why?
|
| Calibration | 4 | 2020 | 818 | 0.180 |
Why?
|
| Drug Dosage Calculations | 2 | 2011 | 117 | 0.180 |
Why?
|
| Spironolactone | 1 | 2024 | 412 | 0.180 |
Why?
|
| Costs and Cost Analysis | 4 | 2009 | 1668 | 0.180 |
Why?
|
| Drug Therapy | 2 | 2001 | 503 | 0.170 |
Why?
|
| Vision Disorders | 5 | 2012 | 1088 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2016 | 1533 | 0.170 |
Why?
|
| Reproducibility of Results | 17 | 2019 | 20098 | 0.170 |
Why?
|
| Pyridones | 3 | 2024 | 809 | 0.170 |
Why?
|
| Self Disclosure | 6 | 2005 | 249 | 0.170 |
Why?
|
| Ophthalmoscopy | 1 | 2020 | 171 | 0.170 |
Why?
|
| Polymorphism, Genetic | 6 | 2011 | 4243 | 0.170 |
Why?
|
| Vitamin B 6 | 2 | 2016 | 234 | 0.170 |
Why?
|
| Restless Legs Syndrome | 2 | 2013 | 233 | 0.170 |
Why?
|
| Sodium | 5 | 2022 | 1588 | 0.170 |
Why?
|
| Lipoproteins, VLDL | 2 | 2017 | 201 | 0.170 |
Why?
|
| Group II Phospholipases A2 | 1 | 2019 | 12 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 15936 | 0.170 |
Why?
|
| tau Proteins | 2 | 2020 | 2095 | 0.170 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1069 | 0.170 |
Why?
|
| Diabetic Nephropathies | 3 | 2018 | 973 | 0.160 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2000 | 738 | 0.160 |
Why?
|
| Analgesics | 4 | 2017 | 1070 | 0.160 |
Why?
|
| Fluorouracil | 2 | 2015 | 1641 | 0.160 |
Why?
|
| Health Services | 5 | 2010 | 752 | 0.160 |
Why?
|
| Area Under Curve | 4 | 2021 | 1638 | 0.160 |
Why?
|
| Kidney Transplantation | 4 | 2008 | 4234 | 0.160 |
Why?
|
| Trabeculectomy | 2 | 1993 | 174 | 0.160 |
Why?
|
| Optic Neuritis | 1 | 2021 | 174 | 0.160 |
Why?
|
| Statistics as Topic | 4 | 2011 | 2358 | 0.160 |
Why?
|
| Diabetic Neuropathies | 2 | 2018 | 405 | 0.160 |
Why?
|
| Medically Uninsured | 3 | 2013 | 836 | 0.160 |
Why?
|
| Melanoma | 13 | 2022 | 5709 | 0.160 |
Why?
|
| Glycoproteins | 2 | 2016 | 2203 | 0.160 |
Why?
|
| Treatment Refusal | 3 | 1998 | 429 | 0.160 |
Why?
|
| Stapes Surgery | 2 | 2001 | 60 | 0.160 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1998 | 39 | 0.160 |
Why?
|
| Thalidomide | 1 | 2024 | 885 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2019 | 17904 | 0.160 |
Why?
|
| Vestibular Nerve | 4 | 2000 | 101 | 0.150 |
Why?
|
| Simvastatin | 2 | 2012 | 346 | 0.150 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2018 | 34 | 0.150 |
Why?
|
| Disease Progression | 12 | 2020 | 13506 | 0.150 |
Why?
|
| Hand Joints | 1 | 2018 | 58 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 211 | 0.150 |
Why?
|
| Glucose | 7 | 2022 | 4346 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2022 | 560 | 0.150 |
Why?
|
| Body Size | 2 | 2015 | 463 | 0.150 |
Why?
|
| Psychotic Disorders | 3 | 2024 | 3223 | 0.150 |
Why?
|
| Blood Coagulation | 2 | 2017 | 1154 | 0.150 |
Why?
|
| Angioedema | 1 | 2019 | 184 | 0.150 |
Why?
|
| Health Personnel | 10 | 2024 | 3335 | 0.150 |
Why?
|
| Hip Fractures | 5 | 2011 | 988 | 0.150 |
Why?
|
| Milk, Human | 1 | 2022 | 486 | 0.150 |
Why?
|
| Butyrates | 1 | 2018 | 169 | 0.150 |
Why?
|
| Age Distribution | 8 | 2020 | 2880 | 0.150 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 52 | 0.150 |
Why?
|
| Benzoxazoles | 1 | 2018 | 90 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 239 | 0.150 |
Why?
|
| Prognosis | 18 | 2022 | 29625 | 0.150 |
Why?
|
| Placebos | 7 | 2020 | 1667 | 0.140 |
Why?
|
| Homocysteine | 4 | 2022 | 638 | 0.140 |
Why?
|
| Selenium | 1 | 2020 | 417 | 0.140 |
Why?
|
| Angioplasty | 2 | 2010 | 355 | 0.140 |
Why?
|
| Tetrazoles | 3 | 2008 | 909 | 0.140 |
Why?
|
| Staff Development | 1 | 2019 | 228 | 0.140 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 215 | 0.140 |
Why?
|
| Medical Records | 4 | 2018 | 1408 | 0.140 |
Why?
|
| Peptic Ulcer | 2 | 2009 | 217 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2018 | 23445 | 0.140 |
Why?
|
| Gestational Age | 3 | 2020 | 3577 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2169 | 0.140 |
Why?
|
| Mental Status Schedule | 2 | 1999 | 314 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2017 | 2208 | 0.140 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 1998 | 0.140 |
Why?
|
| Peritoneal Dialysis | 3 | 2002 | 159 | 0.140 |
Why?
|
| Pravastatin | 5 | 2006 | 392 | 0.140 |
Why?
|
| Disease Management | 2 | 2018 | 2508 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 130 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 4174 | 0.140 |
Why?
|
| Anemia | 2 | 2020 | 1509 | 0.140 |
Why?
|
| Hospital Information Systems | 1 | 2019 | 394 | 0.140 |
Why?
|
| Haloperidol | 1 | 2018 | 389 | 0.130 |
Why?
|
| Laser Therapy | 3 | 1997 | 1092 | 0.130 |
Why?
|
| Lens Implantation, Intraocular | 1 | 1998 | 191 | 0.130 |
Why?
|
| Acetylgalactosamine | 1 | 2016 | 38 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 1010 | 0.130 |
Why?
|
| Child | 17 | 2023 | 80153 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 981 | 0.130 |
Why?
|
| Colonic Neoplasms | 3 | 2015 | 2538 | 0.130 |
Why?
|
| Hair Cells, Vestibular | 3 | 2000 | 50 | 0.130 |
Why?
|
| Dementia | 2 | 2022 | 2686 | 0.130 |
Why?
|
| Brain Ischemia | 6 | 2013 | 3049 | 0.130 |
Why?
|
| Adolescent | 34 | 2024 | 88319 | 0.130 |
Why?
|
| Azithromycin | 2 | 2019 | 199 | 0.130 |
Why?
|
| Infant, Premature | 2 | 2022 | 2107 | 0.130 |
Why?
|
| Retinopathy of Prematurity | 1 | 2020 | 439 | 0.130 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 283 | 0.130 |
Why?
|
| Hypotension | 2 | 2002 | 879 | 0.130 |
Why?
|
| Risk Management | 1 | 2019 | 558 | 0.120 |
Why?
|
| Benzothiadiazines | 5 | 2001 | 31 | 0.120 |
Why?
|
| Insurance Claim Reporting | 3 | 2007 | 166 | 0.120 |
Why?
|
| Selenomethionine | 1 | 2015 | 18 | 0.120 |
Why?
|
| Incretins | 1 | 2016 | 99 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2017 | 1555 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1089 | 0.120 |
Why?
|
| Cochlea | 3 | 1990 | 845 | 0.120 |
Why?
|
| Prejudice | 2 | 2010 | 570 | 0.120 |
Why?
|
| Clinical Trials as Topic | 6 | 2015 | 8002 | 0.120 |
Why?
|
| Refractive Errors | 1 | 2017 | 147 | 0.120 |
Why?
|
| Pneumonia | 2 | 2020 | 2143 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2015 | 225 | 0.120 |
Why?
|
| Factor V | 3 | 2009 | 167 | 0.120 |
Why?
|
| Telemedicine | 2 | 2024 | 3051 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2008 | 705 | 0.120 |
Why?
|
| Spiral Ganglion | 4 | 2000 | 177 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 69 | 0.120 |
Why?
|
| Diuretics | 8 | 2009 | 610 | 0.120 |
Why?
|
| Administration, Oral | 7 | 2024 | 4021 | 0.120 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 5 | 2001 | 78 | 0.120 |
Why?
|
| Lactones | 2 | 2009 | 317 | 0.120 |
Why?
|
| Clinical Medicine | 1 | 1996 | 145 | 0.120 |
Why?
|
| Smoking Cessation | 3 | 2016 | 2056 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 4 | 2001 | 781 | 0.120 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1189 | 0.120 |
Why?
|
| Massachusetts | 16 | 2021 | 8830 | 0.120 |
Why?
|
| Vision Tests | 2 | 1994 | 161 | 0.120 |
Why?
|
| Hospital Mortality | 6 | 2018 | 5294 | 0.120 |
Why?
|
| Laurence-Moon Syndrome | 1 | 1993 | 9 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 992 | 0.110 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 4420 | 0.110 |
Why?
|
| Health Expenditures | 8 | 2012 | 2366 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2007 | 350 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4016 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2014 | 119 | 0.110 |
Why?
|
| Boston | 15 | 2019 | 9326 | 0.110 |
Why?
|
| Coronary Artery Bypass | 3 | 2013 | 2188 | 0.110 |
Why?
|
| Kidney | 7 | 2021 | 7048 | 0.110 |
Why?
|
| Canada | 3 | 2010 | 2122 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2017 | 853 | 0.110 |
Why?
|
| Cognition Disorders | 5 | 2013 | 3979 | 0.110 |
Why?
|
| Endpoint Determination | 5 | 2018 | 590 | 0.110 |
Why?
|
| Thiazoles | 2 | 2018 | 1517 | 0.110 |
Why?
|
| Temporal Bone | 3 | 1999 | 683 | 0.110 |
Why?
|
| Renin-Angiotensin System | 2 | 2008 | 737 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 2244 | 0.110 |
Why?
|
| Sarcopenia | 1 | 2018 | 372 | 0.110 |
Why?
|
| Renal Insufficiency | 3 | 2005 | 809 | 0.110 |
Why?
|
| alpha-Linolenic Acid | 1 | 2014 | 144 | 0.110 |
Why?
|
| Severity of Illness Index | 12 | 2023 | 15842 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 3 | 2017 | 1792 | 0.110 |
Why?
|
| Hematuria | 1 | 2014 | 233 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 7 | 2008 | 1624 | 0.110 |
Why?
|
| Gout Suppressants | 1 | 2015 | 177 | 0.110 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3358 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2020 | 5112 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1664 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 703 | 0.110 |
Why?
|
| Retina | 2 | 2021 | 2659 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 1112 | 0.100 |
Why?
|
| Employment | 2 | 2012 | 1118 | 0.100 |
Why?
|
| Morbidity | 3 | 2017 | 1750 | 0.100 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 675 | 0.100 |
Why?
|
| Ketolides | 1 | 2012 | 12 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 1039 | 0.100 |
Why?
|
| Financing, Personal | 2 | 2012 | 309 | 0.100 |
Why?
|
| Decision Making | 3 | 2019 | 3929 | 0.100 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 1886 | 0.100 |
Why?
|
| Steroids | 2 | 2009 | 929 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 819 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 7 | 2021 | 2176 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 2759 | 0.100 |
Why?
|
| Skin Neoplasms | 4 | 2022 | 5821 | 0.100 |
Why?
|
| Sensitivity and Specificity | 13 | 2020 | 14666 | 0.100 |
Why?
|
| Patient Discharge | 3 | 2008 | 3443 | 0.100 |
Why?
|
| Geographic Atrophy | 1 | 2013 | 91 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2008 | 431 | 0.100 |
Why?
|
| Alzheimer Disease | 4 | 2020 | 8599 | 0.100 |
Why?
|
| Poisson Distribution | 4 | 2012 | 504 | 0.100 |
Why?
|
| Antibodies | 2 | 2017 | 2418 | 0.100 |
Why?
|
| Survival Rate | 10 | 2017 | 12725 | 0.100 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 339 | 0.100 |
Why?
|
| Alcoholism | 6 | 2005 | 1973 | 0.100 |
Why?
|
| Registries | 8 | 2015 | 8224 | 0.100 |
Why?
|
| Diet Surveys | 3 | 2011 | 1162 | 0.100 |
Why?
|
| Vision, Low | 1 | 1994 | 163 | 0.100 |
Why?
|
| Trans Fatty Acids | 1 | 2013 | 155 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2018 | 6391 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2020 | 901 | 0.100 |
Why?
|
| Inpatients | 2 | 2020 | 2548 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2021 | 2330 | 0.100 |
Why?
|
| Clozapine | 3 | 2005 | 504 | 0.100 |
Why?
|
| Pyridines | 3 | 2017 | 2875 | 0.100 |
Why?
|
| Prothrombin | 3 | 2009 | 191 | 0.100 |
Why?
|
| Azetidines | 1 | 2012 | 142 | 0.100 |
Why?
|
| Data Mining | 2 | 2018 | 551 | 0.100 |
Why?
|
| Carotenoids | 4 | 2008 | 621 | 0.100 |
Why?
|
| False Positive Reactions | 2 | 2012 | 957 | 0.100 |
Why?
|
| Medicaid | 13 | 2021 | 2818 | 0.100 |
Why?
|
| Health Behavior | 4 | 2011 | 2643 | 0.100 |
Why?
|
| Schizophrenia | 3 | 2024 | 6937 | 0.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 2518 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2012 | 494 | 0.090 |
Why?
|
| Social Class | 4 | 2021 | 2004 | 0.090 |
Why?
|
| Corneal Ulcer | 3 | 1991 | 128 | 0.090 |
Why?
|
| Insulin | 3 | 2016 | 6596 | 0.090 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 1992 | 253 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2005 | 2877 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2012 | 641 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 1723 | 0.090 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2016 | 395 | 0.090 |
Why?
|
| Body Constitution | 4 | 2000 | 273 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2024 | 2017 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 140 | 0.090 |
Why?
|
| Labyrinthitis | 1 | 1990 | 32 | 0.090 |
Why?
|
| International Classification of Diseases | 3 | 2011 | 909 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2018 | 1198 | 0.090 |
Why?
|
| Wet Macular Degeneration | 1 | 2013 | 162 | 0.090 |
Why?
|
| Ramipril | 3 | 2001 | 102 | 0.090 |
Why?
|
| Aphakia, Postcataract | 1 | 1991 | 52 | 0.090 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 794 | 0.090 |
Why?
|
| Referral and Consultation | 5 | 2012 | 3600 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 540 | 0.090 |
Why?
|
| Accidental Falls | 3 | 2018 | 1068 | 0.090 |
Why?
|
| Prescriptions | 2 | 2024 | 386 | 0.090 |
Why?
|
| Sepsis | 2 | 2022 | 2585 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4026 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2024 | 4352 | 0.090 |
Why?
|
| Drug Combinations | 5 | 2016 | 2048 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2005 | 184 | 0.090 |
Why?
|
| Retirement | 3 | 1989 | 198 | 0.090 |
Why?
|
| Fructose | 1 | 2012 | 288 | 0.090 |
Why?
|
| Vitamin D | 1 | 2024 | 3303 | 0.090 |
Why?
|
| Exercise | 7 | 2018 | 5890 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2020 | 1525 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 384 | 0.090 |
Why?
|
| Amines | 1 | 2011 | 281 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 445 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 4 | 2021 | 1179 | 0.090 |
Why?
|
| Troponin T | 1 | 2015 | 780 | 0.090 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 649 | 0.090 |
Why?
|
| Biological Products | 1 | 2019 | 914 | 0.090 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2009 | 36 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2011 | 185 | 0.090 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 533 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2018 | 1936 | 0.080 |
Why?
|
| New England | 7 | 1993 | 1054 | 0.080 |
Why?
|
| Health Care Costs | 6 | 2024 | 3242 | 0.080 |
Why?
|
| Marketing | 1 | 2011 | 220 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2021 | 2498 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 819 | 0.080 |
Why?
|
| Models, Biological | 3 | 2018 | 9469 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 2 | 2009 | 112 | 0.080 |
Why?
|
| Stapes | 2 | 2001 | 89 | 0.080 |
Why?
|
| Retinal Degeneration | 1 | 1993 | 413 | 0.080 |
Why?
|
| Contact Lenses | 1 | 1991 | 138 | 0.080 |
Why?
|
| Sulfones | 2 | 2009 | 448 | 0.080 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2008 | 362 | 0.080 |
Why?
|
| Epidemiologic Measurements | 1 | 2009 | 23 | 0.080 |
Why?
|
| Skin | 3 | 2019 | 4484 | 0.080 |
Why?
|
| Fees, Pharmaceutical | 1 | 2009 | 66 | 0.080 |
Why?
|
| Prevalence | 13 | 2024 | 15732 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2001 | 2529 | 0.080 |
Why?
|
| Forecasting | 5 | 2013 | 2928 | 0.080 |
Why?
|
| Deafness | 2 | 1993 | 459 | 0.080 |
Why?
|
| Heart Diseases | 4 | 2015 | 2781 | 0.080 |
Why?
|
| Thiophenes | 1 | 2013 | 569 | 0.080 |
Why?
|
| Otosclerosis | 2 | 2001 | 113 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 16591 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3384 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1068 | 0.080 |
Why?
|
| Digoxin | 2 | 2004 | 246 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 114 | 0.080 |
Why?
|
| Pyridoxine | 1 | 2009 | 108 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2008 | 691 | 0.080 |
Why?
|
| Oval Window, Ear | 2 | 1999 | 21 | 0.080 |
Why?
|
| Fatty Acids | 2 | 2015 | 1808 | 0.080 |
Why?
|
| Medical Assistance | 2 | 2012 | 108 | 0.080 |
Why?
|
| Cochlear Nerve | 1 | 1990 | 202 | 0.080 |
Why?
|
| Neuroma, Acoustic | 1 | 1992 | 459 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 1515 | 0.080 |
Why?
|
| Drug Industry | 2 | 2012 | 788 | 0.080 |
Why?
|
| Immunologic Factors | 3 | 2024 | 1589 | 0.080 |
Why?
|
| Type A Personality | 1 | 1988 | 24 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 2 | 2012 | 822 | 0.080 |
Why?
|
| Facial Paralysis | 1 | 1992 | 346 | 0.080 |
Why?
|
| Hypertension, Renal | 1 | 2008 | 135 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 3889 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1248 | 0.080 |
Why?
|
| Pain | 3 | 2017 | 5073 | 0.080 |
Why?
|
| Neutrophils | 1 | 2021 | 3767 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2012 | 697 | 0.080 |
Why?
|
| Accidents | 1 | 2009 | 165 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 369 | 0.080 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2021 | 364 | 0.070 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 36 | 0.070 |
Why?
|
| Eating | 2 | 2022 | 1539 | 0.070 |
Why?
|
| Neurofilament Proteins | 2 | 2020 | 336 | 0.070 |
Why?
|
| Activated Protein C Resistance | 1 | 2007 | 18 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 2917 | 0.070 |
Why?
|
| Body Weight | 7 | 2017 | 4618 | 0.070 |
Why?
|
| Hydrocodone | 2 | 2022 | 48 | 0.070 |
Why?
|
| Seafood | 1 | 2011 | 393 | 0.070 |
Why?
|
| Tinnitus | 1 | 1990 | 196 | 0.070 |
Why?
|
| Analysis of Variance | 9 | 2011 | 6228 | 0.070 |
Why?
|
| Medical Record Linkage | 2 | 2007 | 285 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2024 | 823 | 0.070 |
Why?
|
| Self Medication | 2 | 2006 | 117 | 0.070 |
Why?
|
| Management Information Systems | 1 | 2007 | 49 | 0.070 |
Why?
|
| Pregnancy | 8 | 2021 | 29874 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 104 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 6484 | 0.070 |
Why?
|
| Alcoholic Intoxication | 2 | 1985 | 174 | 0.070 |
Why?
|
| Research | 1 | 1996 | 1982 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2015 | 1995 | 0.070 |
Why?
|
| Health | 1 | 2010 | 398 | 0.070 |
Why?
|
| Vision Screening | 3 | 2000 | 72 | 0.070 |
Why?
|
| Program Evaluation | 3 | 2019 | 2495 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2009 | 246 | 0.070 |
Why?
|
| Body Height | 4 | 2000 | 1570 | 0.070 |
Why?
|
| Adiponectin | 1 | 2013 | 1113 | 0.070 |
Why?
|
| Piperazines | 2 | 2018 | 2523 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 2244 | 0.070 |
Why?
|
| Intraocular Pressure | 4 | 2007 | 1294 | 0.070 |
Why?
|
| Bone Density | 2 | 2017 | 3551 | 0.070 |
Why?
|
| Osteoporosis | 2 | 2007 | 1606 | 0.070 |
Why?
|
| Epistasis, Genetic | 1 | 2009 | 352 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2012 | 506 | 0.070 |
Why?
|
| Overweight | 2 | 2009 | 2417 | 0.070 |
Why?
|
| Menopause | 1 | 2015 | 1646 | 0.070 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 2947 | 0.070 |
Why?
|
| Heart Atria | 1 | 2013 | 1345 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 3839 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2012 | 589 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1702 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 768 | 0.070 |
Why?
|
| Stroke Volume | 7 | 2024 | 5496 | 0.070 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3963 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 1421 | 0.070 |
Why?
|
| Obesity | 6 | 2024 | 12947 | 0.070 |
Why?
|
| Life Style | 4 | 2014 | 3917 | 0.070 |
Why?
|
| Drug Design | 1 | 2011 | 1048 | 0.070 |
Why?
|
| Contact Lenses, Extended-Wear | 3 | 1991 | 12 | 0.070 |
Why?
|
| Oxycodone | 2 | 2022 | 139 | 0.070 |
Why?
|
| Young Adult | 13 | 2024 | 59243 | 0.070 |
Why?
|
| Echocardiography | 4 | 2014 | 4989 | 0.070 |
Why?
|
| Direct Service Costs | 2 | 2002 | 59 | 0.070 |
Why?
|
| Functional Laterality | 1 | 1993 | 2257 | 0.070 |
Why?
|
| Leisure Activities | 1 | 2007 | 308 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 1992 | 942 | 0.070 |
Why?
|
| Income | 5 | 2011 | 1877 | 0.060 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2022 | 127 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2014 | 1298 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 3416 | 0.060 |
Why?
|
| Contact Lenses, Hydrophilic | 3 | 1991 | 54 | 0.060 |
Why?
|
| Genotype | 6 | 2011 | 12990 | 0.060 |
Why?
|
| Therapeutics | 1 | 2006 | 113 | 0.060 |
Why?
|
| Omeprazole | 1 | 2006 | 105 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 1640 | 0.060 |
Why?
|
| Palliative Care | 2 | 2012 | 3598 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1366 | 0.060 |
Why?
|
| Diet Records | 1 | 2007 | 427 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2005 | 1164 | 0.060 |
Why?
|
| Medication Systems | 1 | 2005 | 32 | 0.060 |
Why?
|
| Infant, Newborn | 8 | 2022 | 26198 | 0.060 |
Why?
|
| Acute-Phase Proteins | 2 | 2016 | 250 | 0.060 |
Why?
|
| Eye Injuries | 1 | 1988 | 227 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 1141 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2007 | 519 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 2 | 2004 | 449 | 0.060 |
Why?
|
| Hearing Loss | 1 | 1992 | 783 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2009 | 3606 | 0.060 |
Why?
|
| Infant | 10 | 2022 | 36192 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1081 | 0.060 |
Why?
|
| Glucocorticoids | 3 | 2008 | 2161 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2024 | 1722 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 204 | 0.060 |
Why?
|
| Creatinine | 7 | 2005 | 1899 | 0.060 |
Why?
|
| Prostatic Diseases | 1 | 1985 | 57 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2007 | 305 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2014 | 2155 | 0.060 |
Why?
|
| Serum Albumin | 1 | 1988 | 672 | 0.060 |
Why?
|
| Virus Diseases | 1 | 1990 | 718 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 750 | 0.060 |
Why?
|
| Guideline Adherence | 4 | 2013 | 2220 | 0.060 |
Why?
|
| Dental Calculus | 1 | 2004 | 12 | 0.060 |
Why?
|
| Educational Status | 5 | 2011 | 2522 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 2 | 2024 | 2190 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2008 | 1055 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2024 | 84 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 5336 | 0.060 |
Why?
|
| Bacteriuria | 2 | 1995 | 102 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2009 | 937 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2093 | 0.060 |
Why?
|
| Anthocyanins | 1 | 2024 | 80 | 0.060 |
Why?
|
| Plasma Substitutes | 1 | 2003 | 57 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2024 | 114 | 0.060 |
Why?
|
| Arthritis | 2 | 2008 | 680 | 0.060 |
Why?
|
| Age of Onset | 2 | 2021 | 3305 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2009 | 448 | 0.060 |
Why?
|
| Chromatography, Gas | 2 | 2014 | 151 | 0.050 |
Why?
|
| Sex Distribution | 4 | 2012 | 2281 | 0.050 |
Why?
|
| Ophthalmic Solutions | 3 | 2000 | 313 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2014 | 4159 | 0.050 |
Why?
|
| Hospice Care | 1 | 2010 | 678 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 1474 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2023 | 141 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 2921 | 0.050 |
Why?
|
| Quality of Life | 5 | 2018 | 13367 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 1287 | 0.050 |
Why?
|
| Jews | 1 | 1985 | 356 | 0.050 |
Why?
|
| Cell Count | 6 | 2000 | 1835 | 0.050 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 7 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2005 | 461 | 0.050 |
Why?
|
| Mineral Oil | 1 | 2022 | 21 | 0.050 |
Why?
|
| Postmenopause | 3 | 2022 | 2513 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2008 | 3204 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 1687 | 0.050 |
Why?
|
| Aortic Diseases | 1 | 2008 | 735 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2012 | 787 | 0.050 |
Why?
|
| Ireland | 2 | 2018 | 170 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 615 | 0.050 |
Why?
|
| Hormones | 1 | 2006 | 869 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 13639 | 0.050 |
Why?
|
| Rate Setting and Review | 1 | 2002 | 41 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 88 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 142 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 1208 | 0.050 |
Why?
|
| Nursing Homes | 4 | 1999 | 1082 | 0.050 |
Why?
|
| Neutropenia | 2 | 2017 | 885 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 112 | 0.050 |
Why?
|
| Vestibule, Labyrinth | 2 | 2001 | 234 | 0.050 |
Why?
|
| Keratitis | 3 | 1989 | 241 | 0.050 |
Why?
|
| Health Maintenance Organizations | 3 | 2004 | 659 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2016 | 509 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 336 | 0.050 |
Why?
|
| Dopamine Antagonists | 1 | 2002 | 288 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.050 |
Why?
|
| Locomotion | 2 | 1994 | 388 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 11118 | 0.050 |
Why?
|
| Gingiva | 1 | 2004 | 410 | 0.050 |
Why?
|
| Germany | 2 | 2018 | 875 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2005 | 1755 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15631 | 0.050 |
Why?
|
| Mothers | 2 | 2022 | 2198 | 0.050 |
Why?
|
| Factor VIII | 2 | 2006 | 348 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 211 | 0.050 |
Why?
|
| Accreditation | 1 | 2024 | 473 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 284 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2024 | 3769 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2017 | 186 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 3879 | 0.050 |
Why?
|
| Polypharmacy | 2 | 2018 | 306 | 0.050 |
Why?
|
| Nutrition Assessment | 2 | 2018 | 728 | 0.050 |
Why?
|
| Glycosylation | 1 | 2024 | 1098 | 0.050 |
Why?
|
| Catecholamines | 1 | 2001 | 386 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2006 | 858 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 6814 | 0.050 |
Why?
|
| Education, Distance | 1 | 2024 | 261 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 93 | 0.040 |
Why?
|
| Ventricular Remodeling | 2 | 2014 | 1267 | 0.040 |
Why?
|
| Reference Values | 6 | 2012 | 4920 | 0.040 |
Why?
|
| Long-Term Care | 2 | 2002 | 633 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3778 | 0.040 |
Why?
|
| Pulse | 1 | 2000 | 217 | 0.040 |
Why?
|
| Miotics | 1 | 2000 | 9 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2004 | 385 | 0.040 |
Why?
|
| Albuminuria | 2 | 2018 | 657 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 5 | 2017 | 7407 | 0.040 |
Why?
|
| Terminal Care | 1 | 2012 | 1760 | 0.040 |
Why?
|
| Neprilysin | 1 | 2023 | 478 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2004 | 512 | 0.040 |
Why?
|
| Aldehyde Reductase | 1 | 2000 | 71 | 0.040 |
Why?
|
| Weight Loss | 1 | 2012 | 2684 | 0.040 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 13380 | 0.040 |
Why?
|
| Fruit | 2 | 2017 | 1160 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2002 | 282 | 0.040 |
Why?
|
| Vasculitis | 1 | 2024 | 521 | 0.040 |
Why?
|
| Health Status | 5 | 2007 | 4077 | 0.040 |
Why?
|
| Alleles | 2 | 2009 | 6863 | 0.040 |
Why?
|
| Lactation | 1 | 2022 | 397 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2016 | 4686 | 0.040 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 7879 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 803 | 0.040 |
Why?
|
| Apolipoprotein A-I | 2 | 2013 | 299 | 0.040 |
Why?
|
| Remission Induction | 2 | 2020 | 2396 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1273 | 0.040 |
Why?
|
| Prone Position | 1 | 2021 | 196 | 0.040 |
Why?
|
| Macrolides | 1 | 2021 | 205 | 0.040 |
Why?
|
| Acute Disease | 2 | 2007 | 7237 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 774 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2001 | 338 | 0.040 |
Why?
|
| Self Report | 3 | 2019 | 3724 | 0.040 |
Why?
|
| Homes for the Aged | 2 | 1999 | 272 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 767 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2011 | 5492 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 520 | 0.040 |
Why?
|
| Utah | 1 | 2019 | 131 | 0.040 |
Why?
|
| Anthropometry | 2 | 1983 | 1349 | 0.040 |
Why?
|
| Probability | 2 | 2021 | 2477 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2012 | 4481 | 0.040 |
Why?
|
| Arthralgia | 1 | 2023 | 461 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 2113 | 0.040 |
Why?
|
| Ethanol | 2 | 2003 | 1324 | 0.040 |
Why?
|
| Mandibular Neoplasms | 1 | 2000 | 130 | 0.040 |
Why?
|
| Death, Sudden | 1 | 2021 | 301 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 448 | 0.040 |
Why?
|
| Child, Preschool | 9 | 2020 | 42230 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2019 | 86 | 0.040 |
Why?
|
| Administration, Inhalation | 3 | 2008 | 1157 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 539 | 0.040 |
Why?
|
| Asthma | 3 | 2008 | 6234 | 0.040 |
Why?
|
| Meniere Disease | 1 | 2000 | 164 | 0.040 |
Why?
|
| Accidents, Home | 1 | 2018 | 71 | 0.040 |
Why?
|
| Social Environment | 1 | 1983 | 1020 | 0.040 |
Why?
|
| Length of Stay | 4 | 2017 | 6425 | 0.040 |
Why?
|
| Women | 1 | 2000 | 223 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2000 | 134 | 0.040 |
Why?
|
| alpha-Tocopherol | 2 | 2008 | 126 | 0.040 |
Why?
|
| Cardiomegaly | 1 | 2001 | 590 | 0.040 |
Why?
|
| Program Development | 1 | 2024 | 1297 | 0.040 |
Why?
|
| Imidazoles | 2 | 2003 | 1180 | 0.040 |
Why?
|
| Transaminases | 1 | 2018 | 198 | 0.040 |
Why?
|
| Contraception Behavior | 1 | 2000 | 182 | 0.040 |
Why?
|
| Incus | 1 | 1997 | 19 | 0.040 |
Why?
|
| Pyuria | 2 | 1995 | 30 | 0.040 |
Why?
|
| Otitis Media, Suppurative | 1 | 1997 | 27 | 0.040 |
Why?
|
| Enalapril | 1 | 1999 | 312 | 0.040 |
Why?
|
| Ossicular Prosthesis | 1 | 1997 | 36 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 1092 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 2496 | 0.040 |
Why?
|
| Motor Activity | 1 | 2007 | 2715 | 0.040 |
Why?
|
| International Cooperation | 1 | 2024 | 1422 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2008 | 1909 | 0.040 |
Why?
|
| Hospices | 2 | 2012 | 245 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2002 | 567 | 0.040 |
Why?
|
| Depressive Disorder | 2 | 2005 | 3728 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 325 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 585 | 0.040 |
Why?
|
| Ear Ossicles | 1 | 1997 | 71 | 0.040 |
Why?
|
| Cholesterol, VLDL | 1 | 2017 | 70 | 0.040 |
Why?
|
| Marriage | 3 | 1993 | 351 | 0.040 |
Why?
|
| Motivation | 3 | 1988 | 2006 | 0.040 |
Why?
|
| Mass Screening | 1 | 1993 | 5428 | 0.040 |
Why?
|
| Alcoholic Beverages | 1 | 1999 | 264 | 0.040 |
Why?
|
| Information Systems | 1 | 1999 | 396 | 0.040 |
Why?
|
| Mastoid | 1 | 1997 | 100 | 0.030 |
Why?
|
| Reoperation | 3 | 1997 | 4303 | 0.030 |
Why?
|
| Bone Conduction | 1 | 1997 | 102 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2010 | 3745 | 0.030 |
Why?
|
| Phacoemulsification | 1 | 1998 | 149 | 0.030 |
Why?
|
| Prostate | 1 | 1985 | 1770 | 0.030 |
Why?
|
| Hearing Loss, Conductive | 1 | 1997 | 159 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 289 | 0.030 |
Why?
|
| Patient Participation | 1 | 2005 | 1444 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2018 | 590 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 1992 | 1080 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 4544 | 0.030 |
Why?
|
| Benchmarking | 2 | 2015 | 1045 | 0.030 |
Why?
|
| Eye Enucleation | 3 | 1992 | 128 | 0.030 |
Why?
|
| Femur Neck | 1 | 2017 | 314 | 0.030 |
Why?
|
| Risperidone | 1 | 2018 | 381 | 0.030 |
Why?
|
| Retreatment | 2 | 2011 | 598 | 0.030 |
Why?
|
| Occupations | 2 | 2000 | 515 | 0.030 |
Why?
|
| Observer Variation | 3 | 1999 | 2606 | 0.030 |
Why?
|
| Antidepressive Agents | 2 | 2005 | 2897 | 0.030 |
Why?
|
| Blood Proteins | 2 | 2016 | 1173 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2001 | 935 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 3810 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2019 | 463 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1896 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2017 | 2645 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 1995 | 145 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 579 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 1880 | 0.030 |
Why?
|
| Ear, Middle | 1 | 1997 | 339 | 0.030 |
Why?
|
| Muscular Diseases | 2 | 2010 | 553 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2004 | 1175 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1998 | 360 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 832 | 0.030 |
Why?
|
| Otitis Media | 1 | 1997 | 286 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2000 | 596 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2001 | 1725 | 0.030 |
Why?
|
| Cost Savings | 3 | 2006 | 913 | 0.030 |
Why?
|
| Ion Transport | 1 | 2015 | 319 | 0.030 |
Why?
|
| Ibuprofen | 1 | 1996 | 229 | 0.030 |
Why?
|
| Kidney Function Tests | 3 | 2003 | 678 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2024 | 1388 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 2 | 1997 | 999 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 190 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2000 | 358 | 0.030 |
Why?
|
| Lipoproteins | 2 | 2016 | 881 | 0.030 |
Why?
|
| Diabetic Foot | 1 | 2018 | 380 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2022 | 1359 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3712 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 664 | 0.030 |
Why?
|
| Fishes | 1 | 2017 | 603 | 0.030 |
Why?
|
| Episode of Care | 1 | 1994 | 128 | 0.030 |
Why?
|
| Meat | 1 | 2017 | 584 | 0.030 |
Why?
|
| Poverty | 2 | 2018 | 2698 | 0.030 |
Why?
|
| Dairy Products | 1 | 2017 | 490 | 0.030 |
Why?
|
| Binomial Distribution | 1 | 1993 | 23 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 174 | 0.030 |
Why?
|
| Hearing | 1 | 1997 | 501 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1990 | 1596 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2024 | 1277 | 0.030 |
Why?
|
| Maternal Behavior | 1 | 2015 | 307 | 0.030 |
Why?
|
| Speech Reception Threshold Test | 1 | 1992 | 16 | 0.030 |
Why?
|
| Speech Discrimination Tests | 1 | 1992 | 35 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2021 | 2612 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1997 | 959 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 452 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2020 | 834 | 0.030 |
Why?
|
| Audiometry, Evoked Response | 1 | 1992 | 45 | 0.030 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 411 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 1499 | 0.030 |
Why?
|
| Dark Adaptation | 1 | 1993 | 222 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2013 | 149 | 0.030 |
Why?
|
| Joint Diseases | 1 | 1996 | 459 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 1993 | 377 | 0.030 |
Why?
|
| Death Certificates | 2 | 2006 | 167 | 0.020 |
Why?
|
| Prediabetic State | 1 | 2018 | 545 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1997 | 1204 | 0.020 |
Why?
|
| Therapeutic Equivalency | 2 | 2002 | 134 | 0.020 |
Why?
|
| Health Planning Support | 1 | 2011 | 8 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 2013 | 158 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2015 | 222 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Half-Life | 2 | 2004 | 651 | 0.020 |
Why?
|
| Haplotypes | 2 | 2008 | 2713 | 0.020 |
Why?
|
| Vegetables | 1 | 2017 | 1195 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1386 | 0.020 |
Why?
|
| Population Surveillance | 2 | 1999 | 2598 | 0.020 |
Why?
|
| Electroretinography | 1 | 1993 | 525 | 0.020 |
Why?
|
| Medicare Part B | 1 | 2012 | 117 | 0.020 |
Why?
|
| Nonprescription Drugs | 1 | 1992 | 118 | 0.020 |
Why?
|
| Retinal Detachment | 3 | 1990 | 428 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1087 | 0.020 |
Why?
|
| Dextropropoxyphene | 1 | 2010 | 26 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 4761 | 0.020 |
Why?
|
| Adenine | 1 | 2017 | 987 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 461 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 412 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 395 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 1996 | 940 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2021 | 3023 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 413 | 0.020 |
Why?
|
| Codeine | 1 | 2010 | 51 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2000 | 1225 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2012 | 157 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2013 | 326 | 0.020 |
Why?
|
| Eye Color | 1 | 1990 | 36 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2629 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2012 | 573 | 0.020 |
Why?
|
| Creatine Kinase | 2 | 2004 | 685 | 0.020 |
Why?
|
| Self Administration | 3 | 1998 | 390 | 0.020 |
Why?
|
| Exercise Test | 1 | 2018 | 2127 | 0.020 |
Why?
|
| Premenopause | 1 | 2015 | 1039 | 0.020 |
Why?
|
| Peptides | 1 | 2022 | 4358 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1450 | 0.020 |
Why?
|
| Vitamin K | 1 | 1993 | 318 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 588 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 437 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 1996 | 598 | 0.020 |
Why?
|
| Liability, Legal | 1 | 2011 | 210 | 0.020 |
Why?
|
| Heterozygote | 1 | 1997 | 2787 | 0.020 |
Why?
|
| Otolaryngology | 1 | 1997 | 693 | 0.020 |
Why?
|
| Classification | 1 | 1990 | 127 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2919 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 69 | 0.020 |
Why?
|
| Drug Recalls | 1 | 2009 | 20 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 897 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 3708 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1572 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2001 | 7045 | 0.020 |
Why?
|
| Ciliary Body | 1 | 1990 | 167 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1181 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1989 | 66 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2012 | 290 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 11121 | 0.020 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2009 | 46 | 0.020 |
Why?
|
| Iris | 1 | 1990 | 232 | 0.020 |
Why?
|
| Coronary Angiography | 2 | 2016 | 4471 | 0.020 |
Why?
|
| Particle Size | 1 | 2013 | 1648 | 0.020 |
Why?
|
| Choroid Neoplasms | 1 | 1990 | 177 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 646 | 0.020 |
Why?
|
| Food Handling | 1 | 2009 | 154 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 771 | 0.020 |
Why?
|
| Macula Lutea | 2 | 1987 | 177 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2012 | 337 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 793 | 0.020 |
Why?
|
| Social Support | 2 | 2002 | 2171 | 0.020 |
Why?
|
| Hirudins | 1 | 2009 | 179 | 0.020 |
Why?
|
| Blindness | 1 | 1992 | 584 | 0.020 |
Why?
|
| Factor VII | 1 | 2009 | 139 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1993 | 1132 | 0.020 |
Why?
|
| Beverages | 1 | 1994 | 821 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2009 | 139 | 0.020 |
Why?
|
| Temperance | 1 | 1988 | 87 | 0.020 |
Why?
|
| Piperidines | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 1994 | 1007 | 0.020 |
Why?
|
| Financing, Government | 1 | 2012 | 472 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 6019 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1879 | 0.020 |
Why?
|
| Argon | 1 | 1987 | 36 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2008 | 94 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2008 | 161 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1157 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2012 | 907 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 1380 | 0.020 |
Why?
|
| Hair Cells, Auditory | 1 | 1990 | 381 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2285 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1852 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2008 | 153 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2825 | 0.020 |
Why?
|
| Poisoning | 1 | 2009 | 252 | 0.020 |
Why?
|
| Lutein | 1 | 2008 | 123 | 0.020 |
Why?
|
| Texas | 1 | 2008 | 404 | 0.020 |
Why?
|
| Sclera | 1 | 1989 | 190 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2012 | 334 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2007 | 91 | 0.020 |
Why?
|
| Feeding Behavior | 2 | 2011 | 3188 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2009 | 219 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2009 | 350 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 1994 | 883 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2006 | 48 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4124 | 0.020 |
Why?
|
| Fovea Centralis | 1 | 1987 | 126 | 0.020 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 32 | 0.020 |
Why?
|
| Stents | 1 | 2018 | 3179 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 585 | 0.020 |
Why?
|
| State Health Plans | 1 | 2008 | 219 | 0.020 |
Why?
|
| Death | 1 | 2010 | 676 | 0.020 |
Why?
|
| Atrophy | 1 | 1990 | 1633 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 1091 | 0.020 |
Why?
|
| Hospitals | 1 | 2019 | 3882 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 197 | 0.020 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1989 | 328 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 130 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3270 | 0.020 |
Why?
|
| Emphysema | 1 | 2008 | 238 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2016 | 3096 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2012 | 1051 | 0.020 |
Why?
|
| Adiposity | 1 | 2015 | 1878 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 1989 | 339 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 532 | 0.010 |
Why?
|
| Hospitals, Teaching | 2 | 2001 | 1156 | 0.010 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1993 | 1376 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3801 | 0.010 |
Why?
|
| Administration, Topical | 2 | 1997 | 704 | 0.010 |
Why?
|
| Aerosols | 1 | 2006 | 635 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2009 | 1175 | 0.010 |
Why?
|
| Pruritus | 1 | 2006 | 380 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.010 |
Why?
|
| Connecticut | 2 | 1994 | 364 | 0.010 |
Why?
|
| Urban Population | 2 | 1988 | 2036 | 0.010 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2002 | 22 | 0.010 |
Why?
|
| Hemodialysis, Home | 1 | 2002 | 20 | 0.010 |
Why?
|
| Medical Audit | 1 | 2004 | 453 | 0.010 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 27 | 0.010 |
Why?
|
| Scotland | 1 | 2002 | 143 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2003 | 280 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1987 | 1813 | 0.010 |
Why?
|
| Optic Disk | 1 | 1987 | 421 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 364 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2557 | 0.010 |
Why?
|
| Software Design | 1 | 2002 | 171 | 0.010 |
Why?
|
| Risk-Taking | 1 | 1988 | 1038 | 0.010 |
Why?
|
| Value of Life | 1 | 2002 | 98 | 0.010 |
Why?
|
| Naproxen | 1 | 2002 | 100 | 0.010 |
Why?
|
| Interpersonal Relations | 2 | 1993 | 1436 | 0.010 |
Why?
|
| Chicago | 1 | 2002 | 254 | 0.010 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2002 | 87 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2014 | 3807 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 597 | 0.010 |
Why?
|
| Ofloxacin | 1 | 2001 | 66 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1985 | 1152 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 395 | 0.010 |
Why?
|
| Social Values | 1 | 2002 | 225 | 0.010 |
Why?
|
| Physician-Patient Relations | 2 | 2005 | 3249 | 0.010 |
Why?
|
| Ankylosis | 1 | 2001 | 39 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3357 | 0.010 |
Why?
|
| Epoprostenol | 1 | 2001 | 247 | 0.010 |
Why?
|
| Troponin | 1 | 2004 | 502 | 0.010 |
Why?
|
| Reference Standards | 1 | 2004 | 1003 | 0.010 |
Why?
|
| Prolactin | 1 | 2002 | 625 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2004 | 518 | 0.010 |
Why?
|
| Streptomycin | 1 | 2000 | 69 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1390 | 0.010 |
Why?
|
| Kanamycin | 1 | 2000 | 63 | 0.010 |
Why?
|
| Time | 1 | 2002 | 546 | 0.010 |
Why?
|
| Walking | 1 | 2007 | 1198 | 0.010 |
Why?
|
| Neomycin | 1 | 2000 | 92 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3550 | 0.010 |
Why?
|
| Tars | 1 | 1980 | 20 | 0.010 |
Why?
|
| Cephalosporins | 1 | 2001 | 198 | 0.010 |
Why?
|
| Caffeine | 1 | 1985 | 700 | 0.010 |
Why?
|
| MEDLINE | 1 | 2000 | 119 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6534 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 307 | 0.010 |
Why?
|
| Premature Birth | 1 | 2012 | 1782 | 0.010 |
Why?
|
| Cost Control | 1 | 2002 | 628 | 0.010 |
Why?
|
| Joints | 1 | 2001 | 322 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2002 | 499 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 186 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 3220 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2001 | 897 | 0.010 |
Why?
|
| Dementia, Vascular | 1 | 2000 | 122 | 0.010 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2002 | 292 | 0.010 |
Why?
|
| Exfoliation Syndrome | 1 | 2000 | 113 | 0.010 |
Why?
|
| Physician's Role | 1 | 2005 | 917 | 0.010 |
Why?
|
| Keratins | 1 | 2000 | 498 | 0.010 |
Why?
|
| Protons | 3 | 1989 | 1116 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2001 | 849 | 0.010 |
Why?
|
| Marital Status | 1 | 2000 | 426 | 0.010 |
Why?
|
| Beer | 1 | 1999 | 134 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2001 | 916 | 0.010 |
Why?
|
| Wine | 1 | 1999 | 166 | 0.010 |
Why?
|
| Epinephrine | 1 | 2001 | 792 | 0.010 |
Why?
|
| Photography | 2 | 1992 | 532 | 0.010 |
Why?
|
| Biopsy | 3 | 1999 | 6766 | 0.010 |
Why?
|
| Netherlands | 1 | 2002 | 2221 | 0.010 |
Why?
|
| Thorax | 1 | 1981 | 555 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 633 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 751 | 0.010 |
Why?
|
| Granulation Tissue | 1 | 1997 | 92 | 0.010 |
Why?
|
| Burns | 1 | 2009 | 1882 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 527 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2003 | 1444 | 0.010 |
Why?
|
| Cholesteatoma, Middle Ear | 1 | 1997 | 52 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 601 | 0.010 |
Why?
|
| Tobacco Use Disorder | 1 | 1983 | 703 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 952 | 0.010 |
Why?
|
| Population | 1 | 1997 | 141 | 0.010 |
Why?
|
| Troponin I | 1 | 2001 | 651 | 0.010 |
Why?
|
| Protein C | 1 | 1997 | 133 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3290 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2008 | 2321 | 0.010 |
Why?
|
| Ear Canal | 1 | 1997 | 147 | 0.010 |
Why?
|
| Family Health | 1 | 2001 | 1257 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 2491 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 5972 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 2001 | 888 | 0.010 |
Why?
|
| Interviews as Topic | 2 | 1996 | 2696 | 0.010 |
Why?
|
| Reagent Strips | 1 | 1995 | 39 | 0.010 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1995 | 99 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1902 | 0.010 |
Why?
|
| Weight Gain | 1 | 2005 | 2348 | 0.010 |
Why?
|
| Nicotine | 1 | 1980 | 680 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1995 | 330 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 1995 | 189 | 0.010 |
Why?
|
| Dopamine | 1 | 2001 | 1607 | 0.010 |
Why?
|
| Respiration | 1 | 1981 | 1657 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1996 | 276 | 0.010 |
Why?
|
| Cell Size | 1 | 1996 | 624 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 983 | 0.010 |
Why?
|
| Noise | 1 | 1996 | 290 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1996 | 640 | 0.010 |
Why?
|
| Renin | 1 | 1996 | 641 | 0.010 |
Why?
|
| Teaching | 1 | 2001 | 1170 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2002 | 2025 | 0.010 |
Why?
|
| Intestinal Polyps | 1 | 1993 | 104 | 0.010 |
Why?
|
| Iowa | 1 | 1992 | 104 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 2469 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 2561 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1989 | 9000 | 0.010 |
Why?
|
| Mutation | 1 | 1997 | 30052 | 0.010 |
Why?
|
| Postal Service | 1 | 1992 | 96 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1997 | 1083 | 0.010 |
Why?
|
| Arteries | 1 | 1997 | 1123 | 0.010 |
Why?
|
| Urinalysis | 1 | 1994 | 368 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 3595 | 0.010 |
Why?
|
| Mammography | 1 | 2002 | 2430 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 1995 | 518 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2001 | 2979 | 0.010 |
Why?
|
| Health Promotion | 1 | 2002 | 2214 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 3627 | 0.010 |
Why?
|
| Vital Capacity | 2 | 1984 | 971 | 0.010 |
Why?
|
| Glaucoma, Neovascular | 1 | 1989 | 37 | 0.010 |
Why?
|
| Estrogens | 1 | 1996 | 1522 | 0.010 |
Why?
|
| Altitude | 1 | 1990 | 163 | 0.010 |
Why?
|
| Hygiene | 1 | 1989 | 94 | 0.010 |
Why?
|
| Compliance | 1 | 1989 | 100 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 4414 | 0.000 |
Why?
|
| Urinary Tract Infections | 1 | 1995 | 802 | 0.000 |
Why?
|
| Mental Disorders | 1 | 2008 | 6845 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 2000 | 3312 | 0.000 |
Why?
|
| Sunlight | 1 | 1990 | 337 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1988 | 193 | 0.000 |
Why?
|
| Demography | 1 | 1993 | 1648 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2656 | 0.000 |
Why?
|
| Animals | 2 | 2017 | 168459 | 0.000 |
Why?
|
| Axons | 1 | 1996 | 1674 | 0.000 |
Why?
|
| Knee Joint | 1 | 1996 | 1676 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7856 | 0.000 |
Why?
|
| Iris Diseases | 1 | 1987 | 37 | 0.000 |
Why?
|
| Personality | 1 | 1990 | 554 | 0.000 |
Why?
|
| Hand | 1 | 1992 | 902 | 0.000 |
Why?
|
| Memory | 1 | 1996 | 2188 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11076 | 0.000 |
Why?
|
| Medical History Taking | 1 | 1990 | 774 | 0.000 |
Why?
|
| Lung | 1 | 1984 | 10000 | 0.000 |
Why?
|
| Social Adjustment | 1 | 1988 | 632 | 0.000 |
Why?
|
| Liver Neoplasms | 2 | 1992 | 4320 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1989 | 1085 | 0.000 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 42 | 0.000 |
Why?
|
| Eye | 1 | 1989 | 712 | 0.000 |
Why?
|
| Bacteria | 1 | 1995 | 2199 | 0.000 |
Why?
|
| Physical Examination | 1 | 1990 | 1255 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 12974 | 0.000 |
Why?
|
| Cell Survival | 1 | 1993 | 5791 | 0.000 |
Why?
|
| Orosomucoid | 1 | 1982 | 45 | 0.000 |
Why?
|
| Pedigree | 1 | 1990 | 4542 | 0.000 |
Why?
|
| Complement Factor B | 1 | 1982 | 57 | 0.000 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1982 | 167 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9280 | 0.000 |
Why?
|
| Spirometry | 1 | 1984 | 929 | 0.000 |
Why?
|
| Haptoglobins | 1 | 1982 | 166 | 0.000 |
Why?
|
| Internship and Residency | 1 | 2001 | 5880 | 0.000 |
Why?
|
| Cornea | 1 | 1989 | 1333 | 0.000 |
Why?
|
| Skinfold Thickness | 1 | 1981 | 162 | 0.000 |
Why?
|
| Retinal Diseases | 1 | 1987 | 705 | 0.000 |
Why?
|
| Platelet Function Tests | 1 | 1982 | 271 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1991 | 4915 | 0.000 |
Why?
|
| Platelet Count | 1 | 1982 | 781 | 0.000 |
Why?
|
| Life Change Events | 1 | 1984 | 952 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1982 | 771 | 0.000 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1983 | 625 | 0.000 |
Why?
|
| Collagen | 1 | 1982 | 2638 | 0.000 |
Why?
|